Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin Combined With Gemcitabine in Pancreatic Cancer
NCT05903703Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of canagliflozin in pancreatic cancer (PC) (2 arms). Primary endpoint: Clinical Response (CR, PR, SD, PD) at 18 weeks. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
canagliflozin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05903703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903703.